EUVIMEDAtrasti EUVIMED
Crossref

Differential Proteomic Profiling of Cerebrospinal Fluid Shows Potential for the Diagnosis of Degenerative Cervical Myelopathy

Jianhua Zheng iD, Jinchao Wang, Xiaopeng Zhang iD, Liguo Liu iD, Qinpeng Song, Penglei Cui iD, Xiao Han

PROTEOMICS – Clinical Applications · 2026-11 · 20 (6)

DOI: 10.1002/prca.70063 ↗

At a glance

Journal article in PROTEOMICS – Clinical Applications, published online on 2026-11-04. Written by Jianhua Zheng and 6 co-authors. Institution: NHC Key Laboratory of Systems Biology of Pathogens, National Institute of Pathogen Biology, and Center for Tuberculosis Research, Chinese Academy of …. Major MEDLINE topics: Proteomics, Spinal Cord Diseases. 47 references. Funded by: National Science and Technology Major Project, Kunlun Talents•High-end Innovation and Entrepreneurship Talent project of Qinghai Province in 2025, Capital's Funds for Health Improvement and Research.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Degenerative cervical myelopathy (DCM) is the main neurodegenerative cause of spinal cord dysfunction and impairment. Due to its atypical clinical symptoms, the lack of reliable biomarkers to sensitively evaluate the degree of neurodegeneration has hindered the diagnosis and treatment. Label‐free quantitative proteomics was applied to analyze the cerebrospinal fluid (CSF) samples from DCM and non‐DCM control (Control) subjects, and another cohort was collected for parallel reaction monitoring (PRM) validation analysis. Overall, 1502 proteins were identified, and 120 proteins were differentially expressed. Furthermore, eight promising CSF biomarkers linked to a wide range of pathophysiologies in DCM were successfully validated by using PRM in an independent cohort, and the diagnostic values of those were assessed by receiver operating characteristic (ROC) analyses. Among them, six proteins demonstrated the ability to discriminate DCM patients from non‐DCM control (AUC>0.85). Moreover, the combination of CADM1 and MANBA achieved the highest diagnostic accuracy with an AUC of 0.959. This study presents the first quantitative proteomic analysis of human CSF from DCM. The results may help understand the pathophysiology of DCM and provide insight into identifying objective criteria for the diagnosis of DCM in clinical applications. Summary This study presents the first quantitative proteomic analysis of human cerebrospinal fluid (CSF) from degenerative cervical myelopathy (DCM). Label‐free quantitative proteomics was applied to analyze the CSF samples from DCM and Control subjects, and the identified and differentially expressed proteins underwent extensive bioinformatics analyses. Eight promising CSF biomarkers linked to a wide range of pathophysiologies in DCM were successfully validated by using PRM in an independent cohort, and the diagnostic values of those were assessed by ROC analyses; the combination of CADM1 and MANBA achieved the highest diagnostic accuracy with an AUC of 0.959. The results may help understand the pathophysiology of DCM and provide an insight into identifying objective criteria for the diagnosis of DCM in clinical applications.

Subjects

MeSH terms (MEDLINE)

ProteomicsSpinal Cord DiseasesHumansBiomarkersFemaleMaleMiddle AgedCervical VertebraeAgedROC Curve

Author keywords

cerebrospinal fluiddegenerative cervical myelopathydiagnosisparallel reaction monitoringproteomic profiling

Substances

Biomarkers

Authors and institutions

  • NHC Key Laboratory of Systems Biology of Pathogens, National Institute of Pathogen Biology, and Center for Tuberculosis Research, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Qinghai Institute for Endemic Disease Prevention and Control, Xining, Qinhai Province, China.
  • Department of Spine Surgery, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
  • Gastrointestinal Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.

ORCID profiles: Jianhua Zheng, Xiaopeng Zhang, Liguo Liu, Penglei Cui

Funding

  • National Science and Technology Major Project
  • Kunlun Talents•High-end Innovation and Entrepreneurship Talent project of Qinghai Province in 2025
  • Capital's Funds for Health Improvement and Research
  • Beijing Jishuitan Hospital Elite Young Scholar Programme

Cite

APA

Zheng, J., Wang, J., Zhang, X., Liu, L., Song, Q., Cui, P., & Han, X. (2026). Differential Proteomic Profiling of Cerebrospinal Fluid Shows Potential for the Diagnosis of Degenerative Cervical Myelopathy. PROTEOMICS – Clinical Applications, 20(6). https://doi.org/10.1002/prca.70063

Vancouver

Zheng J, Wang J, Zhang X, Liu L, Song Q, Cui P, et al. Differential Proteomic Profiling of Cerebrospinal Fluid Shows Potential for the Diagnosis of Degenerative Cervical Myelopathy. PROTEOMICS – Clinical Applications. 2026;20(6). doi:10.1002/prca.70063

BibTeX
@article{Zheng2026,
  author = {Zheng, Jianhua and Wang, Jinchao and Zhang, Xiaopeng and Liu, Liguo and Song, Qinpeng and Cui, Penglei and Han, Xiao},
  title = {Differential Proteomic Profiling of Cerebrospinal Fluid Shows Potential for the Diagnosis of Degenerative Cervical Myelopathy},
  journal = {PROTEOMICS – Clinical Applications},
  year = {2026},
  volume = {20},
  number = {6},
  doi = {10.1002/prca.70063}
}
Start for free →